Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)

US9260492B2 · kind B2 · utility

Assignee

• Pieris AG · DE

Inventors

• Gabriele Matschiner · Munich, DE
• Andreas Hohlbaum · Paunzhausen, DE
• Kristian Jensen · Munich, DE

Key dates

• Filing date: Nov 15, 2011
• Grant date: Feb 16, 2016
• Expiry date: Jul 16, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N9/96
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described are specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins include muteins of a lipocalin protein, such as lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.